GE HealthCare Technologies Inc. (BVMF:GEHC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 187.99B -0.2% |
| Revenue (ttm) | 112.08B +6.9% |
| Net Income | 11.15B -2.8% |
| EPS | 3.22 -2.1% |
| Shares Out | n/a |
| PE Ratio | 15.25 |
| Forward PE | 14.33 |
| Dividend | 0.06 (0.13%) |
| Ex-Dividend Date | Oct 22, 2026 |
| Volume | n/a |
| Open | 49.04 |
| Previous Close | 49.04 |
| Day's Range | 49.04 - 49.04 |
| 52-Week Range | 37.98 - 60.61 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About BVMF:GEHC34
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, BVMF:GEHC34's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial numbers in USD Financial StatementsNews
GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today introduced Allia™ Celeo,* a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in...
GE HealthCare price target raised to $90 from $80 at RBC Capital
RBC Capital analyst Shagun Singh raised the firm’s price target on GE HealthCare (GEHC) to $90 from $80 and keeps an Outperform rating on the shares. The company’s 6.2% organic…
GE HealthCare price target raised to $80 from $70 at JPMorgan
JPMorgan raised the firm’s price target on GE HealthCare (GEHC) to $80 from $70 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $90 from $85 at Mizuho
Mizuho raised the firm’s price target on GE HealthCare (GEHC) to $90 from $85 and keeps an Outperform rating on the shares.
GE HealthCare price target raised to $79 from $71 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on GE HealthCare (GEHC) to $79 from $71 and keeps a Neutral rating on the shares.
GE HealthCare price target raised to $84 from $74 at BofA
BofA raised the firm’s price target on GE HealthCare (GEHC) to $84 from $74 and keeps a Neutral rating on the shares, citing both higher peer multiples and better order…
GE HealthCare price target raised to $95 from $85 at Barclays
Barclays analyst Christopher Pasquale raised the firm’s price target on GE HealthCare (GEHC) to $95 from $85 and keeps an Overweight rating on the shares post the Q3 report. The…
GE HealthCare Technologies Earnings Call Transcript: Q3 2026
Q3 revenue grew 6.2% organically, adjusted EBIT margin expanded 180 bps and adjusted EPS rose 25.1%. Full-year 2026 guidance was raised, with strong backlog and broad segment growth.
GE HealthCare reports Q3 adjusted EPS $1.34, consensus $1.20
Reports Q3 revenue $5.5B, consensus $5.35B. GE HealthCare (GEHC) President and CEO Peter Arduini said, “We delivered strong top-line growth and margin expansion across all segments, and robust EPS gro...
GE HealthCare reports third quarter 2026 financial results
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2026. GE HealthCare President and CEO Peter Arduini said, “We delivere...
GE HealthCare announces five new collaborations for StarGuide GX
GE HealthCare (GEHC) announced a global clinical evaluation program spanning three continents and five institutions to assess StarGuide GX, its next-generation digital 4D SPECT/CT system. Participatin...
GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging
CHICAGO & VIENNA--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a global clinical evaluation program spanning three continents and five internationally recognized institutions to asses...
GE HealthCare adds LOGIQ Focus to its portfolio
GE HealthCare (GEHC) announced LOGIQ Focus, a new addition to its LOGIQ family of general imaging ultrasound systems, designed to bring advanced imaging tools to a broader range of ultrasound…
GE HealthCare expands general imaging ultrasound portfolio with LOGIQ Focus, elevating everyday ultrasound performance
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced LOGIQ™ Focus, a new addition to its LOGIQ family of general imaging ultrasound systems, designed to bring advanced imaging tools to a broader ra...
GE HealthCare announces publication of research on End-tidal Control software
GE HealthCare (GEHC) announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in...
Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a l...
GE HealthCare’s MINItrace Magni achieves CE Mark, PETtrace expands
GE HealthCare (GEHC) announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 production....
GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-6...
GE HealthCare price target lowered to $75 from $79 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on GE HealthCare (GEHC) to $75 from $79 and keeps a Buy rating on the shares as part of a broader…
GE HealthCare to announce third quarter 2026 results on October 28, 2026
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team ...
GE HealthCare initiated with an Overweight at Barclays
Barclays initiated coverage of GE HealthCare (GEHC) with an Overweight rating and $85 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture and distribute PET ima...
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North ...
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans
The deal expands GE HealthCare's footprint in radiopharmaceuticals, its fastest-growing segment.